The growth rate of income and profit is under pressure. The main business of private family holding Jimin Pharmaceutical is large infusion and injection puncture equipment, and it is also working with the hospital to set up a hemodialysis center. adopt the business of hospital operation and the company's exclusive provision of supplies for hemodialysis.
The company's operating income for 11-14 years was 548 million, 583 million, 559 million and 488 million (2014 data were unaudited), with a compound growth rate of-3.8%. In 11-14, the net profits attributed to the parent company were 68 million, 75 million, 81 million and 58 million (2014 data are unaudited), with a compound growth rate of 5.3%. In 2013-2014, revenue decreased compared with the same period last year, and profits declined in 2014, due to the continued impact of special regulation of antibiotics. Provinces are brewing a new round of bidding, dealers are cautious in purchasing, and the sharp drop in profits is due to rising costs.
The larger drop was due to higher costs.
Large infusion is the company's main source of income. Jimin Pharmaceutical's business is mainly large infusion, which is mainly soft bags and plastic bottle products. Since 2011, large infusion has accounted for more than 80% of the company's revenue. From January to September 2014, large infusion accounted for 80.78% of the company's income, including 67.54% of soft bag narrow companies and 13.24% of plastic bottles.
Medical devices are the company's second largest business, accounting for an increasing proportion of the company's revenue in recent years, accounting for 19.22% of the company's revenue from January to September 2014, mainly safety syringes and aseptic syringes, while infusion devices account for relatively small.
Fund-raising project to expand non-PVC soft bag large infusion capacity Jimin Pharmaceutical plans to issue no more than 40 million shares and raise 377 million capital. It mainly plans to invest in non-PVC soft bag-related projects, partly for R & D center construction and supplementary liquidity.
Reasonable value range: 7.6-9.5 yuan
